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Abstract 
Objectives 
Antiepileptic  drugs  have  been  used  in  pain  management  since  the  1960s.  Pregabalin  is  a  recently 
developed antiepileptic drug also used in management of chronic neuropathic pain conditions. The aim of 
this observational prospective study was to assess the analgesic efficacy and associated adverse events of 
pregabalin in treated patients with neuropathic pain. The source of medication was the free samples that 
have been provided by the company for evaluation. 
Methods 
Neurologists and Endocrinologists at king Hussein Medical Center prescribed Pregabalin for selected 
patients (no. =50) who were diagnosed to have neuropathic pain according to pre-formulated questionnaire 
that was developed by researchers. The majority of patients received Pregabalin 150mg as a starting dose, 
300 mg as a maintenance dose for three months. then the magnitude of pain was assessed first after  one 
week  of  treatment,  if  the  patient  had  pain  relief  after  one  week  and  maintained  on  treatment  further 
assessment was performed at intervals of one, two and three months. Then for each patient the average 
score of pain relief was calculated (0=worst value, 10=best value).patients were also encouraged to report 
any adverse effect during treatment period.   
Results 
  A total of 50 patients with neuropathic pain were included. During the course of the study 17 patients 
terminated treatment during the first week (but were replaced by other 15 patients) either due to lack of 
efficacy (12%, n=6) or due to intolerable adverse effects (22%, n= 11). For the remaining patients the 
average score of pain relief was 2.8 ±1.2. The average score of pain reduction was higher among patients 
with  diabetic  neuropathy  (3.4)  than  with  other  types  of  neuropathic  pain  (2.2).  The  most  frequently 
reported adverse effects were dizziness, fatigue, somnolence, and gastrointestinal disturbances. 
Conclusion 
  Pregabalin  is  effective  in  reducing  diabetic  neuropathy  and  to  a  lesser  extent  than  other  types  of 
neuropathic pain. (But) However intolerable adverse effects still face a problem. Further studies comparing 
its efficacy and tolerability with other neuropathic treatment choices are needed. 
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Introduction 
Neuropathic  pain,  caused  by  a  lesion  of  the 
nervous  system  is  especially  problematic. 
(1,2) 
because; it is often experienced in parts of the 
body  that  otherwise  appear  normal,  it  is 
generally chronic, severe and resistant to over-
the-counter  analgesics,  and    it  is  further 
aggravated  by  allodynia  (touch-evoked 
pain).
(3,4,  5)  It  may  result  from  various  causes 
that affect the brain, spinal cord and peripheral 
nerves,  including  cervical  or  lumbar 
radiculopathy,  diabetic  neuropathy,  cancer-
related       neuropathic   pain,    postherpetic  
 
neuralgia, HIV-related neuropathy, spinal cord 
injury, trigeminal neuralgia  
and complex regional pain syndrome type II. 
(6) The 
epidemiology  of  neuropathic  pain  has  not  been 
adequately studied, partly because of the diversity 
of  the  associated  conditions.  Current  pooled 
estimates suggest that neuropathic pain may affect 
as much as 3% of the population. 
(7–13) 
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Characterization of Neuropathic Pain 
Symptoms  described by patients  with  neuropathic 
pain  are  numerous,  representing  a  variety  of 
possible nerve injuries implicated in causation. 
(14)  
Neuropathic pain sufferers complain of numbness, 
burning, or tingling,or a combination; they describe 
electric  shock–like,  prickly,  or  pins  and  needles 
sensations.  Patients  completing  the  McGill  Pain 
Questionnaire 
(15) described their pain using terms 
such as “punishing-cruel” and “tiring-exhausting.” 
In 1990, Boureau et al 
(16) identified six adjectives 
used  substantially  more  frequently  to  describe 
neuropathic  pain;  electric  shock,  burning,  and 
tingling were most commonly used (53%, 54%, 
and  48%,  respectively),  in  addition  to  cold, 
pricking, and itching.These terms should suggest 
a neuropathic etiology for pain. Table 1 defines 
the sensory symptoms and signs associated with 
neuropathic pain.
(1) 
 
Table 1: Sensory Symptoms and Signs Associated With Neuropathic Pain 
Symptom or Sign  Description 
Allodynia  Pain due to non-noxious stimuli (clothing, light touch) when applied 
to the affected area. May be mechanical (e.g., caused by light 
pressure), dynamic (caused by non painful movement of a stimulus), 
or thermal (caused by non painful warm, or cool stimulus). 
 
Anesthesia  Loss of normal sensation to the affected region. 
 
Dysesthesia  Spontaneous or evoked unpleasant 
abnormal sensations. 
 
Hyperalgesia  Reduction of normal sensation to the affected region. 
Paresthesias  Non painful spontaneous abnormal sensations. 
Phantom  Pain from a specific site that no longer exists (e.g., 
amputated limb) or where there is no current injury. 
 
Referred Pain  Occurs in a region remote from the source. 
 
Assessing Neuropathic Pain 
Recently,  pain  researchers  have  focused 
attention on a theory that accurate measurement 
of  pain  quality  could  provide  insight  into 
treatment effects too subtle to be noticed when 
global measures are similar. 
(18) This accuracy 
is  especially  important  for  neuropathic  pain, 
because  specific  sensory  characteristics  (e.g., 
burning,  tingling)  may  spotlight 
pathophysiologic mechanisms of such pain and 
give clues to those types of intervention most 
likely to result in palliation. Pain scales provide 
useful,  standardized,  and  validated  tools  for 
charting  an  individual’s  response  to  a  pain-
control  intervention.  In  addition,  detailed 
documentation utilizing accepted pain scales to 
assess a patient’s level of discomfort provides 
protection from legal challenges regarding any 
prescribed pharmacotherapy. 
(17) 
Neuropathic pain medications 
Medications  used  to  treat  neuropathic  pain 
include over-the-counter analgesics,  
 
anticonvulsants,  tricyclic  antidepressants 
(TCAs), and selective serotonin-norepinephrine 
reuptake inhibitors (SSNRIs), topical anesthetic 
agents,  nonsteroidal  anti-inflammatory  drugs 
(NSAIDs),  antiarrhythmics,  non-narcotic 
analgesics, and opioids. 
(14,  19,  20) All of which 
are reflective of not only the heterogeneity of 
the  patient  population,  but  also  the  varying 
underlying  pathophysiologies  of  neuropathic 
pain. 
Sufficient  evidence  indicates  that  neuropathic 
pain  impairs  patients’  mood,  quality  of  life, 
activities  of  daily  living  and  performance  at 
work.  People  with  the  condition  have  been 
found  to  generate  3-fold  higher  health  care 
costs  compared  with  matched  controls. 
(21) 
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found  in  a  high  percentage  of  patients  with 
neuropathic pain. Treatment failure may be due 
to insufficient analgesic efficacy or early side 
effects that prevent administration of effective 
dose levels. 
For  these  reasons  new  drug  alternatives  that 
may  be  more  efficacious  and  better  tolerated 
are desirable. 
 
Pregabalin  
             Pregabalin  is  a  structural  analog  of  -
aminobutyric  acid  (GABA),  which  shows 
analgesic,  anticonvulsant,  and  anxiolytic 
effects. In many countries, it is approved for the 
treatment  of  neuropathic  pain.  Mechanism  of 
action for pregabalin appears to be the same as 
that for gabapentin; it binds with high affinity 
to  alpha-  2  -gamma  subunits  of  voltage 
activated calcium channels, blocks Ca2+ influx 
into nerve terminals, and decreases transmitter 
release  producing  inhibitory  modulation  of 
“over-excited” neurons and returning them to a 
“normal” state 
(22) 
 
              Pregabalin  has  been  investigated  in 
diabetic  neuropathy  (DPN)  and  postherpetic 
neuralgia  (PHN)  in  few  placebo-controlled 
studies, but data from routine clinical practice 
are not yet sufficient.  
             The  aim  of  this  observational 
prospective  study  was  to  assess  the  analgesic 
efficacy  and  associated  adverse  events  of 
pregabalin  administrated  to  patients  with 
neuropathic pain. The source of medication was 
the free samples that have been provided by the 
company for evaluation  in the Royal Medical 
Services (RMS), Jordan. 
 
Methodology 
The present study was conducted from March 
2011  to  August  2011  as  a  prospective 
observational  study.  Neurologists  and 
Endocrinologists  at  king  Hussein  Medical 
Center  prescribed  Pregabalin  for  selected 
patients (no. =50) who were diagnosed to have 
neuropathic  pain  according  to  pre-formulated 
questionnaire  that  was  developed  by 
researchers.  
         The  majority  of  patients  received 
Pregabalin  at  the  dose  of  150mg  –  300  mg 
administered  in two  or three  individual  doses 
for  three  months.  then  the  magnitude  of  pain 
relief  was  assessed  first  after  one  week  of 
treatment, if the patient had pain relief after one 
week  and  maintained  on  treatment  further 
assessment was performed at intervals of four, 
eight and twelve weeks. Then for each patient 
the average score of pain relief was calculated 
(0=worst value, 10=best value). Patients were 
also  encouraged  to  report  any  adverse  effect 
during treatment period.  
 
Inclusion criteria:  
       Adult  patients  with  NP  from  different 
etiologies  (mainly  diabetic  neuropathy,  inter-
vertebral  disk,  postherpetic  neuralgia)  either 
newly diagnosed or failed to respond to other 
medications. 
Exclusion criteria: 
      Patient  who  did  not  have pain relief after 
one  week  of  treatment  was  excluded  and 
replaced by another patient. 
The questionnaire 
Was  developed  by  researchers  and  included 
four parts:  
Part 1: demographic, medical and drug history 
data 
Part  2:  Yes  or  No  questions  related  to  the 
nature of patient’s pain  
Part  3:  a  numeric  rating  scale  (0-10),  that 
measures patient’s extent of pain relief at each 
assessment  period;  0=no  pain  relief,  10=full 
pain relief  
Part 4: detailed adverse events record (nature, 
time of onset, duration) 
Data Analysis 
         Quantitative  values  were  calculated  as 
mean value and standard deviation. Frequency 
and percentage were calculated and presented. 
Data  from  observation  were  analyzed 
descriptively 
 
Results 
         A  total  of  50  patients  with  neuropathic 
pain were included (table 2). During the course 
of  the  study  17  patients  terminated  treatment 
during  the  first  week  either  due  to  lack  of 
efficacy  (12%,  n=6)  or  due  to  intolerable 
adverse effects (22%, n= 11). 
The excluded patients were replaced by another 
15 patients. So the total number of patients who 
were evaluated for pregabalin efficacy was 48, Pregabalin Efficacy and Tolerability… 
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while  the  side  effects  of  pregabalin  were  evaluated in 65 patients.  
Table 2: Characteristics of Patients Who Participated in the Study 
Characteristic   (n=65) 
Age (mean ± SD) )(range)  (yrs)  56 ± 13.3 
Male (n [%])   38 (58) 
Etiology of Neuropathic Pain 
Diabetic polyneuropathy (n [%])   44 (68) 
Inter-vertebral disk (n [%])   8(12) 
Postherpetic neuralgia (n [%])  7(11) 
Neuropathy of other etiology  (n [%])  6(9) 
Previous analgesic treatments 
NSAIDS and paracetamol(n [%])   8 (12) 
Other Anticonvulsants  6 (9) 
 
Dose delivered during Treatment 
          Pregabalin was prescribed for 12 weeks 
on  an  average.  Overall  22%  stayed  on 
150mg/day  for  the  duration  of  the  study  and 
78% had their dose stepped up to 300mg/day. 
Efficacy 
         The average score of pain relief was 2.8 
±1.2.  The  pain  relief  score  after  one,  four, 
eight, and twelve weeks of treatment were 1.6, 
2.4,  4,  and  3.2  respectively  (Figure  1).The 
average  score  of  pain  reduction  was  higher 
among patients with diabetic neuropathy (3.4) 
compared  to  the  (than  with)  other  types  of 
postherptic  neuralgia,  Inter-vertebral  disk 
neuropathic  pain,  and  neuropathy  of  other 
etiologies  which  was  (3),  (2.6)  and  (2.2) 
respectively (Figure 2).  
Adverse Effects 
         During the course of the study 22%, n= 
11  patients  terminated  treatment  due  to 
intolerable adverse effects (dizziness 46% n=5, 
fatigue  27%  n=3,  somnolence  18%  n=2, 
peripheral edema 9% n=1). 
(In  the)  The  remained  patients  (18.7%  n=9) 
reported mild to moderate adverse effects. The 
most frequently reported adverse  effects were 
dizziness,  fatigue,  somnolence,  and 
gastrointestinal disturbances 
 
Discussion 
         In  this  prospective  observational  study 
Pregabalin  was  evaluated  in  routine  clinical 
practice for its efficacy and tolerability in the 
treatment of neuropathic pain from different  
 
etiologies.  The  (outcomes)  target  was  (that 
were) focused on (were) the score of pain relief 
and  the  tolerability  of  the  drug.  In  summary 
pregabalin showed an acceptable efficacy in the 
treatment of different types of neuropathic pain. 
68%  of  the  evaluated  patients  suffered  from 
diabetic  neuropathy,  12%  suffered  from 
neuropathic  pain  due  to  inter-vertebral  disk, 
11%  suffered  from  neuropathic  pain  due  to 
postherpetic  neuralgia,  and  9%  suffered  from 
neuropathic pain due to other etiologies. 
          (At week one) the first week of the study 
there was a high percent of treatment failure in 
34% of patients either due to lack of efficacy or 
due  to  intolerable  adverse  effects.  Such 
findings  have  been  reported  previously  by 
Arezzo et al. (2008) who found that the (Were) 
the percentage of discontinuations during (his) 
their  randomized,  double-blind,  placebo-
controlled trial  was similar: pregabalin (34%) 
and placebo (28%). Most of these withdrawals 
were  due  to  adverse  events,  with  17% 
discontinuing  pregabalin  and  12% 
discontinuing placebo. During the follow-up of 
the  patients,  adverse  events  were  again 
considered  the  most  common  reason  for 
withdrawal,  with  9%  discontinuing  from  the 
pregabalin  and  6%  discontinuing  from  the 
placebo groups. 
(23) Nairooz H. Al-Momany et al 
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         In  our  study  the  intolerable  adverse 
effects that led patients to terminate treatment 
were  dizziness  46%  n=5,  fatigue  27%  n=3, 
somnolence  18%  n=2,  peripheral  edema  9% 
n=1. 
         The  remained  patients  (18.7%  n=9) 
reported mild to moderate adverse effects. The 
most frequently reported adverse  effects were 
dizziness,  fatigue,  somnolence,  and 
gastrointestinal disturbances. In total 40.7% of 
our patients that were included for the study of 
side  effects  of  pregabalin  experienced  some 
degree of the drug side effects.   
         Pregabalin  was  effective  in  treating 
neuropathic  pain.  The  average  score  of  pain 
relief was 2.8 ±1.2 and it was calculated in a 
simple way that was suggested by researchers 
by  using  a  numeric  rating  scale  (0-10)  that 
measures patient’s extent of pain relief at each 
assessment  period  ;  0=no  pain  relief,  10=full 
pain relief. Analgesic effect of pregabalin was 
observed in patients regardless of etiology, age, 
or  gender.  Administration  of  pregabalin  in 
currently  available  placebo-controlled  studies 
of peripheral neuropathic 
pain  compared  to  placebo  resulted  in  a 
significant  greater  change  in  the  mean  end 
point pain score compared to the baseline score 
. 
(24, 25, 26) 
         For  patients  who  completed  the  study 
(n=48) the extent of pain relief varied between 
patients,  the  pain  relief  differed  from 
neuropathic pain due to different etiologies and 
during  the  period  of  study.  Patients  with 
diabetic  neuropathy  were  the  most  satisfied 
group  of  patients;  the  average  score  of  pain 
relief  in  this  group  was  3.4  out  of  10.  The 
efficacy  and  safety  of  pregabalin  was  further 
reported in a pooled analysis of seven studies 
over 5–11 weeks in 1346 diabetic patients with 
painful neuropathy. 
(27) The response rates were 
46%  (600  mg/day),  39%  (300  mg/day),  27% 
(150 mg/day), and 22% (placebo). The reported 
pain  reduction  in  this  pooled  analysis  is 
comparable  to  our  stated  (reported)  score  of 
pain relief in this group of diabetic patients (3.4 
scores out of 10 =34%) in the same range of 
dose that we used (150-300 mg/day). 
         In patients with postherptic neuralgia was 
used in the present study  (in the current study) 
also showed (reported) a clinically acceptable 
score  of  pain  relief  (3  out  of  10).  In  a  study 
done  by  (were)  Cappuzzo  et.al(2009)  they  
reviewed  the  treatment  of  postherpetic 
neuralgia  with  focus  on  pregabalin  remedy 
concluded  that  despite  positive  findings  with 
several  drug  classes,  the  very  heterogeneous 
nature  of  PHN  makes  successful  pain 
management difficult. Often, trials of more than 
1  agent  are  necessary  before  adequate  pain 
management is achieved. Pregabalin appears to 
be an efficacious, a well-tolerated option for the 
treatment  of  PHN.    The  present  information 
(Data)  suggest  efficacy  for  relief  of  pain  and 
sleep disturbance secondary to PHN in affected 
patients.  Although  there  are  no  head-to-head 
comparisons, pregabalin appears comparable to 
gabapentin  and  other  first-line  agents  for 
treating PHN. 
(28) 
         The  role  of  pregabalin  in  the  treatment 
neuropathic  pain  due  to  other  etiologies  like 
inter-vertebral disk is not well established yet 
although the results of our study showed some 
clinical efficacy  (average score pain reduction 
2.6 out of 10) . 
 
Conclusion 
         Pregabalin  is  effective  in  reducing 
diabetic neuropathy and to a lesser extent other 
types of neuropathic pain. However intolerable 
adverse  effects  and  cost  may  be  an  issue. 
Further  studies  comparing  its  efficacy  and 
tolerability  with  other  neuropathic  treatment 
choices are needed. 
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Figure 1: Average  score of  pain relief 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Average Score of Pain Reduction of Neuropathic pain of Different Etiologies 
DPN: diabetic neuropathy,PHN: postherpetic neuralgia,IVD: intervertebral disk 
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